Kian Sadeghi is on a mission to reshape the landscape of personalized genomics, Through his company, Nucleus Genomics, Sadeghi offers a direct-to-consumer whole genome sequencing test (in partnership with Illumina) that’s easy to use, priced just over $400, and designed to empower individuals to take charge of their genomic data.
At 25 years old and a UPenn college dropout, could Kian become the Bill Gates of this genomics?
In this episode of Behind the Breakthroughs, Kian and I dive headfirst into a range of interwoven topics in personalized genomics: the roles of clinicians and insurers, the power of patient agency, and the differences between direct-to-consumer and clinician-initiated genomics. They also tackle the significant issue of 23andMe's recent bankruptcy, which was once a trailblazer in the industry. Sadeghi shares his perspective on what went wrong and how the lessons from its downfall can shape the future of personalized genomics. Could Sadeghi, 25 years old and a UPenn college dropout, become the Bill Gates of this field? It’s too soon to tell, but his bold ideas and relentless drive are already turning heads.
Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.
Produced by Bill Levine
Hosted by Jonathan D. Grinstein
Audio mixed and mastered by Jason Mack
Music provided by Artem Hramushkin
Hosted on Acast. See acast.com/privacy for more information.
